体重指数与银屑病关节炎患者皮下阿巴西普治疗反应:III期试验事后分析
该研究为III期ASTRAEA试验的事后分析,评估基线体重指数(BMI)对活动性银屑病关节炎患者皮下阿巴西普治疗反应的影响。结果显示,超重或肥胖与正常/低体重亚组相比,第24周各项疗效指标均无显著差异;安慰剂组中肥胖患者达到DAS28(CRP)<2.6的可能性显著更低。结论认为BMI不影响皮下阿巴西普的临床或影像学应答。
要点
- BMI不影响皮下阿巴西普治疗银屑病关节炎的临床或影像学应答。
- 安慰剂组中肥胖患者达到DAS28(CRP)<2.6的可能性显著低于正常/低体重者。
- 该分析为III期ASTRAEA试验的事后分析,样本量有限。
核心结论
- BMI不影响银屑病关节炎患者对皮下阿巴西普的临床或影像学治疗反应。
研究设计与样本
- III期ASTRAEA随机对照试验的事后分析,患者按1:1随机接受盲法每周皮下阿巴西普125 mg或安慰剂治疗24周。
- 阿巴西普组和安慰剂组分别有212/213和210/211例患者具有基线BMI数据。
主要发现
- 阿巴西普组中正常/低体重、超重和肥胖者分别占15%、36%和49%,安慰剂组分别占19%、27%和54%。
- 调整基线特征后,阿巴西普组超重或肥胖与正常/低体重亚组相比,第24周任何结局指标均无显著差异。
- 安慰剂组中肥胖与正常/低体重亚组相比,第24周达到DAS28(CRP)<2.6的可能性显著更低(OR 0.26;95%CI 0.08至0.87;p=0.03)。
关键数值与推荐
- 治疗反应评估包括ACR20应答、DAS28(CRP)≤3.6和<2.6、HAQ-DI较基线下降≥0.35以及影像学无进展(PsA-modified Sharp/van der Heijde评分较基线变化≤0)。
- BMI分层:正常/低体重<25 kg/m2;超重25-30 kg/m2;肥胖>30 kg/m2。
临床怎么用
- 对于银屑病关节炎患者,基线BMI状态不应作为限制皮下阿巴西普使用的依据。
局限性
- 该分析为事后分析,样本量有限,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA). METHODS: In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) ≤3.6 and <2.6, Health Assessment Questionnaire-Disability Index reduction from baseline ≥0.35 and radiographic non-progression (defined as change from baseline ≤0 in PsA-modified total Sharp/van der Heijde score). Responses were stratified by baseline BMI (underweight/normal, <25 kg/m2; overweight, 25-30 kg/m2; obese, >30 kg/m2) and compared in univariate and multivariate models. RESULTS: Of 212/213 and 210/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight/normal subgroup. In the placebo group, patients in the obese versus underweight/normal subgroup were significantly less likely to achieve DAS28 (CRP) <2.6 at week 24 (OR 0.26; 95% CI 0.08 to 0.87; p=0.03). CONCLUSION: BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA. TRIAL REGISTRATION NUMBER: NCT01860976.
引用
- McInnes IB, Ferraccioli G, D'Agostino MA, et al. Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open. 2019. PMID: 31245054. doi:10.1136/rmdopen-2019-000934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。